Skip to main content
22/10/2014

Study in young male prisoners suggest that aggression can be reduced by treating ADHD

2014_0221_IMATGE

22/10/2014

Dr. Ramos-Quiroga, del VHIR, participates in the study through the Aggressotype Consortium

At an international meeting held by the "http://www.aggressotype.eu/" Aggressotype Consortium in Mainz, Germany, researchers from King’s College and Imperial College London presented preliminary results from an on-going treatment study of ADHD in young male prisoners. A team of researchers from the group of "http://www.vhir.org/larecerca/grupsrecerca/ca_grups_equip.asp?Idioma=en&mv1=2&mv2=1&mh1=2&mh2=1&mh3=1&mh4=0&ms=0&area=4&grup=3&menu=3" Psychiatry, mental health and addictions, at the Vall d’Hebron Research Institute (VHIR), led by Dr. Josep Antoni Ramos-Quiroga, is participating in this study through the Aggressotype Consortium.The preliminary results show that 20% of the prisoners met clinical criteria for ADHD. After medical treatment with a long acting stimulant medication there was a large reduction in ADHD symptoms. Improvements with ability to focus attention, restless over activity and impulsive responding were accompanied by greater self-control of behavior and ability to engage positively in educational and rehabilitation programs. Participants reported being less frustrated, irritable and angry, and there was a reduction in aggressive incidents.Aggressotype is a large international consortium funded by the European Union consisting of "http://www.aggressotype.eu/about/members" 18 academic and 6 commercial partners. Aggressotype researchers aim to unravel the biological causes and mechanisms underlying aggression in ADHD and conduct disorder and also investigate how aggression can best be prevented and treated.In their annual meeting this October, the 60 researchers discussed the progress made during a successful first year of their 5-year project, with issues presented covering a wide range of disciplines. Aggressotype represents a unique mix of people with skills and expertise in neuropsychiatry, neuropsychology, preclinical animal and in vitro models, neuroimaging and neurochemistry, genetics and genomics, epigenetics, bioinformatics and biostatistics, clinical pharmacology, regulatory affairs, ethics, valorisation and project management.

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.